|
市場調查報告書
利用蛋白體學的治療藥・診斷藥開發
Know the Other "Omics": Exploring Drug and Diagnostics Development Through Proteomics
|
利用蛋白體學的治療藥・診斷藥開發 是由出版商Decision Resources, Inc.在2009年03月所出版的。
這份英文市場調查報告書包含25 Pages 價格從美金3450起跳。
研究人員目前特別矚目能來監視病情惡化狀態、有效管理疾病、評價有用助於正確診斷藥物標的有效性的蛋白體學。
本報告書內容包括：蛋白體學技術概要及研究過程、矚目蛋白質生物標記的企業、蛋白體學的未來預測等。內容綱要摘記如下：
實施概要
介紹
蛋白質研究的潛在課題
蛋白體學的價值評估
理解蛋白體學方針
- 準備樣本
- 分離、確保、分析、比對
- 臨床評價之前的計畫
近年來與蛋白體學技術相關的動向
蛋白質研究領域的生物醫藥企業
- Caprion Proteomics
- NextGen Sciences
- Power3 Medical products
蛋白體學領域的發展動向
利用蛋白體學之個人化醫療的活性化
- 蛋白體學的進步
- 主要轉捩點
- 作者介紹
- 人體血漿蛋白體學計畫
未來預測
Abstract
Introduction
Genomics has paved the way for its cousin, proteomics, to secure its share of
the "omics" hype. Researchers look to proteomics to deliver on the promise to
assess the viability of drug targets for monitoring disease progression,
optimizing disease management, and diagnosing diseases with more precision.
While many challenges are inherent, given the complexities of protein-centric
science, technological improvements in the fi eld have resulted in important
gains for biopharma.
Get the Answers You Need to Shape Your Strategy
- Partnering in proteomics is slowing despite the potential of the
associated technologies to revolutionize drug discovery, diagnostics
development, and disease management. What problems are inherent in protein
biomarker research? What solutions have been developed to help overcome the
obstacles?
- Navigating the proteomics research process of preparation, separation,
identifi cation, and validation is complex. Which step is most critical
upstream to improve results downstream?
- Proteomics technologies give rise to a select set of protein biomarkers.
What are the differences between biomarkers for drug discovery and those for
diagnostics development?
Scope
- Proteomics technologies: 2DGE, MS, MALDI, SELDI, TOF, bioinformatics.
- Proteomics research process: Innovative methods of sample preparation,
separation and capture, identifi cation and analysis, and clinical validation.
- Companies with valuable insight into protein biomarker discovery:
20/20GeneSystems, Caprion Proteomics, NextGen BioSciences, Oxford
GlycoSciences.
- Outlook: Proteomics is approaching the long-awaited recognition that it
has the potential to deserve. Novel tools now in use will improve greatly
owing to collaborative initiatives that will stimulate innovation in protein research processes.
Table of Contents
Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Inherent Challenges in Researching Proteins
- Proving the Value of Proteomics
- Understanding the Proteomics Approach
- Sample Preparation
- Separation and Capture, Analysis and Identifi cation
- Planning Ahead for Clinical Validation
- Recent Perspectives on Proteomic Technologies
- Two-Dimensional Gel Electrophoresis
- Mass Spectrometry
- Bioinformatics Tools
- Biopharma Players in the Protein Research Arena
- Caprion Proteomics
- NextGen Sciences
- Power3 Medical Products
- Notable Initiatives in Proteomics
- Clinical Proteomic Technologies for Cancer
- Spectrum Expert Commentary
- Revitalizing Personalized Medicine Through Proteomics
- Improvements in Proteomics
- Protein Assay Platforms
- Spectrum Expert Commentary (cont.)
- Assay Availability
- At a Major Turning Point
- About the Author
- Human Plasma Proteome Project
- Outlook
- Overcoming Key Challenges
- Building Capacity Through Collaboration
Tables
- 1. Select Diagnostic Tests Based on Protein Biomarkers
- 2. Advantages and Disadvantages of 2DGE and MS Technologies
- 3. Select Protein Sequencing Databases
- 4. Select Proteomics Companies of Interest
- 5. Participants in the Clinical Proteomic Technologies for Cancer
Initiative
- 6. Pharmaceutical and Diagnostics Company Sponsors of the Human Plasma
Proteome Project
Figures
- 1. FDA Approval of NMEs Compared with R&D Spending, 2000-2008
- 2. Sensitivities and Specifi cities of Select FDA-Approved Protein
Biomarkers
- 3. Proteomics Research Process
- 4. Comparison of Protein Sample Sources
- 5. Number of Alliances Involving Proteomics, 2001-2008
Expert Commentary
- Revitalizing Personalized Medicine Through Proteomics
- M. Walid Qoronfl eh, Ph.D., M.B.A.,
- Vice President of Business Development at NextGen Sciences
|
